ERBB2 and breast cancer: In 45 HER2+BC cases, OS was also not significantly longer in patients with low, compared to patients with high, PD-1, PD-L1 and PD-L2 expressions (p = 0.673, p = 0.620, p = 0.749, log-rank, respectively) (G–I).